focus -WSS

focus

author：hotspot 2025-10-01 02:15:19 - browse：36

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

It was time to plan for my old age. If only I could stop crying

A $475,000 price tag for a new cancer drug: crazy or meh?

Many breast cancer patients receive more radiation than needed

Doctors push to include dialysis machines in emergency stockpile

Apple Vision Pro: A first look at health apps on the new VR headset

entertainment

focus

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

What we need to know about Arena Bioworks

Sports medicine is finally prioritizing gender equality

Time to name cancers by genetics, not organ of origin, expert says

Medical leaders decry Supreme Court decision on affirmative action

Vertigo drug brings hope for rare neuron disorder, Niemann

In age of alternative facts, a scholarly course on calling out crap

Medicare drug price negotiation’s day in court

Trump demands the U.S. pay no more for drugs than other countries … again

Do digital therapeutics have a future in medicine?

entertainment

Novo Nordisk to expand supply of Wegovy for U.S. patients

Judge in Trump's classified documents case questions use of out

'Brian's Song' at 50 still offers lessons about cancer for today

Doctors are clamoring for more clarity on Paxlovid prescribing

Flash flood warnings continue for parts of Missouri, Illinois

ARCH Venture Partners is raising $3 billion for a life sciences fund

focus

knowledge

leisure time

hotspot